Health
Synthetic Mini-Antibody Identified to Combat COVID-19 – SciTechDaily
The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2. To enable the virus to…
SARS-CoV-2’s ability to infect cells relies on interactions between the viral spike protein (magenta) and the protein ACE2 (blue), which is present on the surface of human cells. These interactions can be disrupted by sybodies (black) — synthetic mini-antibodies similar to those produced by camels and llamas. Credit: Rayne Zaayman-Gallant/EMBL
The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2. To enable the virus…
-
Business17 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Business12 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business9 hours agoDicker Data rides the AI trend to double digit growth
-
Business12 hours agoForget CBA shares, this ASX 200 financials stock could be a better buy